Andrea G Lania
Overview
Explore the profile of Andrea G Lania including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
749
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piasentier A, Fanti A, Birtolo M, Vena W, Colle R, Gentile L, et al.
J Endocrinol Invest
. 2025 Jan;
PMID: 39888498
Purpose: The real-world effectiveness of switching from denosumab to romosozumab remains controversial. Sequential therapy with romosozumab was shown to be associated with inadequate suppression of bone resorption and there was...
2.
Vena W, Pigni S, Betella N, Navarra A, Mirani M, Mazziotti G, et al.
Hum Vaccin Immunother
. 2024 Jun;
20(1):2363068.
PMID: 38860457
Purpose: To overview the recent literature regarding the relationship between COVID-19 vaccines and glycemic control. Methods: Data were extracted from text and tables of all available articles published up to...
3.
Jaafar S, Cristofolini G, Morenghi E, Rinaudo L, Birtolo M, Sala E, et al.
Endocrine
. 2024 May;
85(3):1319-1326.
PMID: 38809345
Purpose: The bone strain index (BSI) is a marker of bone deformation based on a finite element analysis inferred from dual X-ray absorptiometry (DXA) scans, that has been proposed as...
4.
Di Muro G, Catalano R, Treppiedi D, Barbieri A, Mangili F, Marra G, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612419
Somatostatin receptor ligands (SRLs) with high affinity for somatostatin receptors 2 and 5 (SSTR2 and SSTR5) are poorly efficacious in NF-PitNETs, expressing high levels of SSTR3. ITF2984 is a pan-SSTR...
5.
Birtolo M, Giannini E, Antonini S, Lavezzi E, Lasio G, Da Rin G, et al.
Pituitary
. 2024 Jan;
27(2):160-168.
PMID: 38170374
Purpose: Identifying patients requiring glucocorticoid replacement therapy after pituitary surgery is challenging as the tests commonly used for the diagnosis of secondary adrenal insufficiency (SAI) are not recommended in the...
6.
De Sousa S, Shen A, Yates C, Clifton-Bligh R, Santoreneos S, King J, et al.
Front Endocrinol (Lausanne)
. 2023 Dec;
14:1305606.
PMID: 38075079
Introduction: Germline loss-of-function variants in , encoding peptidylglycine α-amidating monooxygenase (PAM), were recently discovered to be enriched in conditions of pathological pituitary hypersecretion, specifically: somatotrophinoma, corticotrophinoma, and prolactinoma. PAM is...
7.
Vitali E, Franceschini B, Milana F, Soldani C, Polidoro M, Carriero R, et al.
Liver Int
. 2023 Nov;
44(2):518-531.
PMID: 38010911
Background & Aims: Intrahepatic cholangiocarcinoma (iCCA) is a primary liver tumour, characterized by poor prognosis and lack of effective therapy. The cytoskeleton protein Filamin A (FLNA) is involved in cancer...
8.
Boemi I, Piccini S, Colombo F, Smiroldo V, Zerbi A, Capretti G, et al.
Endocrine
. 2023 Oct;
83(3):810-823.
PMID: 37845576
Purpose: Neuroendocrine neoplasms (NENs) are tumors that arise from cells of the endocrine system and are most common in the gastrointestinal tract, the pancreas, and the lungs. Their incidence is...
9.
Trivellin G, Daly A, Hernandez-Ramirez L, Araldi E, Tatsi C, Dale R, et al.
Front Endocrinol (Lausanne)
. 2023 Jun;
14:1166076.
PMID: 37388215
Introduction: Pituitary adenomas (PAs) are common, usually benign tumors of the anterior pituitary gland which, for the most part, have no known genetic cause. PAs are associated with major clinical...
10.
Borroni R, Piscazzi F, Valenti M, Rimoldi V, Barile M, Bianchi P, et al.
Am J Med Genet A
. 2023 May;
191(8):2249-2251.
PMID: 37141407
No abstract available.